Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from MicroTech Medical (Hangzhou) Co., Ltd. Class H ( (HK:2235) ).
MicroTech Medical reported a sharp turnaround in 2025, driven by surging demand for its continuous glucose monitoring systems in China and abroad. The company’s operating revenue nearly doubled to RMB660.79 million, with CGMS sales rising 150.2% to RMB451.52 million, as its diabetes-focused portfolio gained broader coverage and accessibility.
The group’s gross profit jumped 95.5% and margin improved to 54.1%, supported by a higher CGMS sales mix and economies of scale. Net profit reached RMB40.15 million, reversing a prior-year loss, as rapid international expansion, lean management, and lower ratios of selling and administrative expenses to revenue pushed MicroTech into a new phase of profitable growth.
The most recent analyst rating on (HK:2235) stock is a Sell with a HK$7.00 price target. To see the full list of analyst forecasts on MicroTech Medical (Hangzhou) Co., Ltd. Class H stock, see the HK:2235 Stock Forecast page.
More about MicroTech Medical (Hangzhou) Co., Ltd. Class H
MicroTech Medical (Hangzhou) Co., Ltd. is a China-based medical technology company focused on innovative diabetes management solutions. Its core product is a continuous glucose monitoring system (CGMS), which is sold in both domestic and overseas markets, positioning the group in the fast-growing global glucose monitoring and digital health segment.
Average Trading Volume: 112,441
Technical Sentiment Signal: Sell
Current Market Cap: HK$3B
For detailed information about 2235 stock, go to TipRanks’ Stock Analysis page.